At the heart of Gero’s technology are Large Health Models (LHMs) — physics‑informed, interpretable AI systems trained on vast longitudinal medical records. These models are capable of predicting future health outcomes by learning patterns of aging and disease progression across large populations. Unlike typical black‑box AI tools, Gero’s approach emphasizes physical principles and interpretability, allowing researchers to distinguish between the irreversible aspects of aging and the reversible mechanisms behind chronic diseases. This makes it possible to identify promising therapeutic targets that can be pursued in drug discovery and development.
Gero’s platform integrates rich human data, including genetic sequencing and real‑world health outcomes, to reveal causal pathways and pinpoint novel entrants for drug development. The company collaborates with major pharmaceutical partners and research institutions to accelerate the translation of AI insights into real drug candidates for diseases associated with aging. Its work has attracted attention from industry leaders and scientific experts, reinforcing Gero’s position at the forefront of longevity biotech.
In addition to drug discovery, Gero contributes to the broader scientific understanding of aging by developing digital biomarkers and analytical tools that help quantify biological aging and resilience. With ongoing research and high‑profile collaborations, the company aims to extend healthy human lifespan by targeting the root causes of age‑related decline rather than just treating symptoms.
Overall, Gero represents a new class of biotechnology that blends physics, AI, and human data to tackle some of the most complex health challenges of our time.
